Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the altto phase iii randomized trial
View/ Open
Full Text
Date
2017-05-01Author
Sonnenblick, Amir
Agbor-Tarh, Dominique
Bradbury, Ian
Di Cosimo, Serena
Azim, Hatem A.
Fumagalli, Debora
Sarp, Severine
Wolff, Antonio C.
Andersson, Michael
Kroep, Judith
Cufer, Tanja
Simon, Sergio D.
Salman, Pamela
Toi, Masakazu
Harris, Lyndsay
Gralow, Julie
Keane, Maccon
Moreno-Aspitia, Alvaro
Piccart-Gebhart, Martine
de Azambuja, Evandro
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 61 times in Scopus (view citations)
Recommended Citation
Sonnenblick, Amir; Agbor-Tarh, Dominique; Bradbury, Ian; Di Cosimo, Serena; Azim, Hatem A. Fumagalli, Debora; Sarp, Severine; Wolff, Antonio C.; Andersson, Michael; Kroep, Judith; Cufer, Tanja; Simon, Sergio D.; Salman, Pamela; Toi, Masakazu; Harris, Lyndsay; Gralow, Julie; Keane, Maccon; Moreno-Aspitia, Alvaro; Piccart-Gebhart, Martine; de Azambuja, Evandro (2017). Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the altto phase iii randomized trial. Journal of Clinical Oncology 35 (13),